Sponsor & Developer Portfolio
Takeda
Clinical development pipeline, platform architecture, and registered trial tracking for Takeda vaccine candidates.
4
Candidates
3
Target Diseases
5
Linked Studies
Development Phase Distribution
Phase 3 Clinical Trial: 2 Discontinued / Inactive: 2
Platform Technologies
Biological (unspecified platform): 3 Inactivated: 1
Target Pathogens & Indications
Dengue Polio Zika
Vaccine Pipeline Candidates (4)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Discontinued / Inactive
ctgov-purified-inactivated-zika-virus-vaccine-pizv-takeda
PIZV (TAK-426, purified inactivated Zika virus vaccine)
Target: Zika
Platform: Inactivated
Key Milestone: Primary completion (most advanced trial): 2024-07-05 (registry estimate)
Discontinued / Inactive
ctgov-sabin-based-inactivated-poliomyelitis-vaccine-sipv-takeda
TAK-195 (Sabin-based inactivated poliovirus vaccine, sIPV)
Target: Polio
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2018-04-03 (registry estimate)
Phase 3 Clinical Trial
ctgov-tdv-takeda
TDV
Target: Dengue
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2030-03-03 (registry estimate)
Phase 3 Clinical Trial
ctgov-tetravalent-dengue-vaccine-tdv-takeda
Tetravalent Dengue Vaccine (TDV)
Target: Dengue
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2026-06-29 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.